Picture of Oncolytics Biotech logo

ONCY — Oncolytics Biotech News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapSucker Stock

Brief: Oncolytics Biotech Receives Final Advice Letter From European Medicines Agency For Reolysin In Metastatic Breast Cancer

Dec 5 (Reuters) - Oncolytics Biotech Inc  ONC.TO : 
    * ONCOLYTICS BIOTECH RECEIVES FAVORABLE FINAL ADVICE LETTER 
FROM 
THE EUROPEAN MEDICINES AGENCY FOR REOLYSIN IN METASTATIC BREAST 
CANCER 
    * ONCOLYTICS BIOTECH INC - PROPOSED PHASE 3 STUDY DESIGN IS 
FOUND 
ACCEPTABLE AND CAN FORM BASIS OF A MARKETING AUTHORIZATION 
APPLICATION 
    * ONCOLYTICS BIOTECH INC - EMA ADVICE CONSISTENT WITH 
FEEDBACK 
RECEIVED FROM FDA PAVING WAY FOR A GLOBAL PHASE 3 STUDY 
 
Source text for Eikon:  ID:nCNWP541ba  
Further company coverage:  ONC.TO  
 
 ((Bangalore.newsroom@thomsonreuters.com;))

Recent news on Oncolytics Biotech

See all news